![]() | |
Clinical data | |
---|---|
Trade names | Detectnet |
Other names | Copper Cu 64 dotatate |
License data | |
Routes of administration | Intravenous |
Drug class | Radioactive diagnostic agent[1] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C65H88CuN14O19S2 |
Molar mass | 1497.16 g·mol−1 |
3D model (JSmol) | |
| |
|
Copper (64Cu) oxodotreotide, sold under the brand name Detectnet, is a radioactive diagnostic agent used in positron emission tomography (PET) of neuroendocrine tumors (NETs).[1] Specifically it is used in adults with somatostatin receptor positive disease.[1] It is given by injection into a vein.[1]
Common side effects include nausea, vomiting, and flushing.[1] Other side effects include radiation exposure and allergic reactions.[1] It interacts with somatostatin analogs.[1] Use during pregnancy may harm the baby.[1] It works by binding to somatostatin receptor, particularly subtype 2 receptors.[1]
Copper (64Cu) oxodotreotide was approved for medical use in the United States in 2020.[1] In the United States it costs about 3,900 USD for a vial as of 2022.[2]
References
edit- ^ a b c d e f g h i j k l m "Detectnet- copper cu 64 dotatate injection, solution". DailyMed. 14 September 2020. Archived from the original on 1 November 2022. Retrieved 24 September 2020.
- ^ "Detectnet Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2022. Retrieved 3 November 2022.